Skip to main content
OpenTrials
Completed

NCT Number: NCT06700785

A Pharmacokinetic Comparison of Three Butyrate Products

This study is a randomized, three-arm, interventional study of N=10 apparently healthy men. This study will quantify plasma butyrate responses to a single dose of three different butyrate products.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

The Center for Applied Health Sciences

Canfield, Ohio, 44406, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide voluntary signed and dated informed consent.
  • Be in good health as determined by medical history and routine blood chemistries.
  • Age between the ages of 25 and 45 (inclusive).
  • Body Mass Index of 18.5-24.9 (inclusive).
  • Body weight of at least 110 pounds.
  • Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • Normal seated, resting heart rate (<90 per minute).
  • Willing to duplicate their previous 24-hour diet, refrain from alcohol, caffeine, and exercise for 24 hours and fast for 10 hours prior to each of the treatments.
  • Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Participant is willing and able to comply with the study protocol.

Exclusion criteria

  • A history of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal disease.
  • The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug/alcohol abuse or dependence.
  • History of diabetes (any form) or any endocrine disorder.
  • Fasting blood sugar of > 125 mg/dL.
  • Current smokers or smoking cessation within the past month (28 days).
  • History of hyperparathyroidism or an untreated thyroid disease.
  • History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Any history of gastrointestinal bypass surgery, etc., or any known functional gastrointestinal disorder that may impact nutrient absorption, e.g., short bowel syndrome, atrophic gastritis, IBD, diarrheal illnesses, history of colon resection, gastroparesis, gastric resection, celiac disease, or Inherited Errors of Metabolism (such as PKU).
  • Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV/AIDS, etc.).
  • History of using butyrate or tributyrin-containing dietary supplements within the past seven days.
  • Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.
  • Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Treatment and study plan

Lysine butyrate

Dietary Supplement

Lysine butyrate supplement. This study will compare plasma pharmacokinetic profiles of three commercially available butyrate supplements.

Sodium Butyrate

Dietary Supplement

Oral sodium butyrate supplement.

Tributyrin

Dietary Supplement

Oral tributyrin supplement.

Primary outcomes

  1. plasma butyrate levels

    Time frame: Prior to product administration (time 0), as well as 20, 45, 90, 150, and 210 minutes post-dose

    Plasma butyrate levels in ug/mL.

Secondary outcomes

  1. Visual analog scales for cognitive function.

    Time frame: 0, 20, 45, 90, 150 and 210 minutes post-dose

    Cognitive function as measured by a traditional 10 cm visual analogue scale (VAS), where values can range from 0 to 10, and higher values represent better cognitive function.

  2. Visual analog scales for mood.

    Time frame: 0, 20, 45, 90, 150 and 210 minutes post-dose

    Mood as measured by a traditional 10 cm visual analogue scale (VAS), where values can range from 0 to 10, and higher values represent better mood.

Sponsors and collaborators

Lead sponsor

The Center for Applied Health Sciences, LLC

Industry

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Nov 22, 2024
Registry last updated
Nov 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.